Citi lowered the firm’s price target on Apellis to $88 from $91 and keeps a Buy rating on the shares. The analyst citers dilution from the recent financing for the target drop.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on APLS:
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares
- Sell these stocks now, proven algorithm says
- Apellis 3.17M share Spot Secondary priced at $63.00
- Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants